Cash of $217 Million; CNTY-813 IND in 4Q:26; CNTY-308 in the Clinic This Year

Research evidence excerpt

Cash of $217 Million; CNTY-813 IND in 4Q:26; CNTY-308 in the Clinic This Year

stored 52-Week High / Low US$3.04 / US$0.43

normal glycemic response within 60 minutes. Century will give an oral presentation Shares Out (mil) 205.7

on CNTY-813 data at American Diabetes Association (ADA) on June 8th. (#1318- Form 10Q as of May 1st + PFWs

OR) The promise of CNTY-813 is the ability to replicate the curative potential of islet Market Cap. (mil) US$469.0

transplantation therapy without the need for chronic immunosuppression. Century plans Total Assets ($mil) 327

Avg Daily Vol (000) 1,189 to file the IND in 4Q:26 and report initial data in 2H:27.

Book Value/Share US$1.29

Price/Book 177%

• CNTY-308 to Enter the Clinic in 2026. CNTY-308 is a CD19 αβCAR-iT cell therapy Net Cash Per Share US$1.05

designed to treat B cell autoimmune disease. CNTY-308 is comprised of CD4+/CD8+ Debt to Total Capital 0.0%

αβ T cells equipped with Allo-Evasion 5.0 edits. CNTY-308 expresses a CD19 CAR Div Yield 0.00%

with 4-1BB and CD3z co-stimulatory domains, enabling potent-antigen driven expansion Fiscal Year End Dec

and cytokine secretion. In preclinical studies, CNTY-308 demonstrated long-term in vivo

Price Performance - 1 Year

persistence of 32 days, tumor clearance after re-challenge, high IL-2 secretion and the

ability to eliminate CD19+ B cells from healthy donors. Century has initiated CNTY-308 USD

IND enabling studies and expects to enter the clinic this year. 3.5

2.5

RISKS TO ACHIEVEMENT OF PT & RECOMMENDATION 2

Century's cell therapies may fail in the clinic and the company maybe unable to file new 1.5

INDs. Century will likely require additional cash and may face future litigation.

COMPANY DESCRIPTION 0.5

Century is developing iPSC-derived cell therapies. 0